Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Gains from Investment Securities (2016 - 2024)

Sunshine Biopharma (SBFM) has disclosed Gains from Investment Securities for 4 consecutive years, with -$373529.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Investment Securities changed N/A year-over-year to -$373529.0, compared with a TTM value of -$373529.0 through Sep 2025, down 139.07%, and an annual FY2024 reading of $582483.0, changed N/A over the prior year.
  • Gains from Investment Securities was -$373529.0 for Q4 2024 at Sunshine Biopharma, down from $956012.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $956012.0 in Q1 2024 and bottomed at -$373529.0 in Q4 2024.